Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
Betacoronavirus
/ immunology
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques
Coronavirus Infections
/ diagnosis
Enzyme-Linked Immunosorbent Assay
Female
Hospitalization
/ statistics & numerical data
Humans
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ diagnosis
Point-of-Care Systems
Reagent Kits, Diagnostic
SARS-CoV-2
Sensitivity and Specificity
Seroconversion
Serologic Tests
Young Adult
COVID-19
ELISA
SARS-CoV-2 antibodies
point of care tests
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
13
05
2020
accepted:
28
05
2020
pubmed:
7
6
2020
medline:
14
8
2020
entrez:
7
6
2020
Statut:
ppublish
Résumé
SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests. In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA. Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell® POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon). The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved.
Identifiants
pubmed: 32504735
pii: S0163-4453(20)30376-5
doi: 10.1016/j.jinf.2020.05.077
pmc: PMC7834649
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Reagent Kits, Diagnostic
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e39-e45Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Conflict of Interest The authors declare that there are no conflicts of interest.
Références
J Infect. 2020 Aug;81(2):e53-e54
pubmed: 32335175
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32277023
Public Health. 2020 May;182:170-172
pubmed: 32334183
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
J Med Virol. 2020 Oct;92(10):1724-1727
pubmed: 32227490
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
J Infect. 2020 Jul;81(1):e28-e32
pubmed: 32283141
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Clin Infect Dis. 2020 Nov 19;71(16):2255-2258
pubmed: 32337590
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347204
Lancet Infect Dis. 2020 Apr;20(4):411-412
pubmed: 32105638
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775